# Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis

> **NCT06785974** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 140 (estimated)

## Conditions studied

- Atherosclerosis
- Melanoma
- Immune-related Adverse Event

## Interventions

- **DRUG:** Atorvastatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06785974
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2027-02
- **Final completion:** 2030-02
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06785974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06785974, "Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06785974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*